Rhabdomyosarcoma, an aggressive and often deadly form of cancer has the dismal distinction of survival rates for the intermediate risk group to be between 50 and 70 percent.
But there is some good news on the horizon with a treatment known as differentiation therapy. It emerged when scientists noticed that leukemia cells were still immature compared to undifferentiated stem cells that hadn’t fully differentiated into specific cell types. Differentiation therapy forces these immature leukemia cells to continue their development into specific mature cell types and differentiate successfully.
Learn more: Aggressive Cancer Cells Transformed Into Healthy Cells in Breakthrough
